HMP Global March 3, 2025
In this interview, guest experts John Stahl and Roy Moore explore the evolving payer landscape in 2025, discussing the growing role of value-based agreements, real-world evidence, and innovative reimbursement models in supporting the adoption of precision medicine, GLP-1 therapies, radiopharmaceuticals, and emerging digital health technologies.
Read the Full Transcript
John Stahl: My name is John Stahl. I’m a partner with our commercial strategy consulting team here at Clarivate. I have over 20 years of experience in the health care industry and life sciences space. Here at Clarivate, I lead our US pricing and market access team.
Roy Moore: Thanks for having me. Hi everyone, my name is Roy Moore. I have nearly two decades of experience in the US health...
Today's Sponsors
Today's Sponsor